Abstract

Penfluridol is a new long-acting neuroleptic drug known to be used widely for treating psychotic conditions. An internal standard was employed, which was penfluridol D7 (IS). The analyte and the IS were separated on a Phenomenex Kinetex C18, 5µm 100A, 100*4.6mm column using acetonitrile (40:60, v/v) as the mobile phase and 5 mM ammonium formate as the stationary phase. The retention time of Penfluridol and Penfluridol d7 was set at 2.94 and 2.75 mins respectively. Penfluridol and Penfluridol-d7 were detected and measured using the precursor to product ion transitions of m/z 524.300/203.100 m/z and 531.400/204.100 m/z, respectively. The investigation made use of an API-6500+ LC-MS/MS system running in multiple reactions monitoring (MRM) mode and outfitted with a turbo ion spray (TIS) source.We developed a highly sensitive, selective, and precise method for quantification of Penfluridol in human plasma.

Keyworde: Penfluridol, LC-MS/MS, Antipsychotic, Depot Drug, K2EDTA

Full Text PDF Enter a number greater than 18 Submit

Refrences:

1. Van Praag HM, Schut T, Dols L, Van Schilfgaarden R. Controlled trial of penfluridol in acute psychosis. Br Med J. 1971 Dec 18;4(5789):710-3.
2. Janssen PA, Niemegeers CJ, Schellekens KH, Lenaerts FM, Verbruggen FJ, Van Nueten JM, Marsboom RH, Herin VV, Schaper WK. The pharmacology of fluspirilene (R 6218), a potent, long-acting and injectable neuroleptic drug. Arzneimittel-forschung. 1970 Nov;20(11):1689-98.  
3. Cooper SF, Albert JM. Gas-Liquid Chromatographie Determination of Penfluridol in Plasma. International Pharmacopsychiatry. 1975;10:78-88.  
4. Iversen L, editor. Handbook of Psychopharmacology: Volume 10: Neoroleptics and Schizophrenia. Springer Science & Business Media; 2012 Dec 6.  
5. Airoldi L, Marcucci F, Mussini E, Garattini S. Distribution of penfluridol in rats and mice. European Journal of Pharmacology. 1974 Mar 1;25(3):291-5.  
6. Baro F, Brugmans J, Dom R, Van Lommel R. Maintenance Therapy of Chronic Psychotic Patients with a Weekly Oral Dose of R16 341. A Controlled Double‐Blind Study. The Journal of Clinical Pharmacology and The Journal of New Drugs. 1970 Sep 10;10(5):330-41.  
7. De Wied D, Sigling HO. Neuropeptides involved in the pathophysiology of schizophrenia and major depression. Neurotoxicity research. 2002 Jan 1;4(5-6):453-68.  
8. Haase HJ, Fischer D, Floru L, Frank T, Joseph K, Knaack M, Mohr W, Richter-Peill H, Steuer A, Wahl G, Walterbusch G. Long term neuroleptic therapy using fluspirilene and penfluridol. Der Nervenarzt. 1971 Dec;42(12):632-7.  
9. Möller HJ, Kissling W, Kockott G, Wittmann D. Depot-neuroleptics in acute psychiatry. InPsychiatry the State of the Art 1985 (pp. 763-769). Springer, Boston, MA.  
10. J. Melon, “[Two cases of erotomania treated with penfluridol (R16341)].,” Acta Psychiatr. Belg., 1971 Sep;11(5):414-25.  
11. Ota KY, Kurland AA, Slotnick VB. Safety evaluation of penfluridol, a new long-acting oral antipsychotic agent. Journal of Clinical Pharmacology. 1974 Apr.  
12. Gallant DM, Mielke DH, Spirtes MA, Swanson WC, Bost R. Penfluridol: an efficacious long-acting oral antipsychotic compound. American Journal of Psychiatry. 1974 Jun;131(6):699-702.  
13. Party EW, Committee for Medicinal Products for Human Use. Committee for Medicinal Products for Human Use (CHMP) guideline on Data Monitoring Committees. Statistics in medicine. 2006 May 30;25(10):1639-45.  
14. Fda and Cder, “Bioanalytical Method Validation Guidance for Industry Biopharmaceutics Bioanalytical Method Validation Guidance for Industry Biopharmaceutics Contains Nonbinding Recommendations,” 2018, Accessed: Jul. 09, 2021. [Online]. Available: https://www.fda.gov/files/drugs/published/Bioanalytical-Method-Validation-Guidance-for-Industry.pdf